Ever since the 1980s, when the now-infamous "Turtle Traders" beat the market with simple strategies based on breakouts to new high prices, momentum investing has been shown to be a very profitable strategy. In fact, many academics now...
CLSN — Celsion Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapSucker Stock
- $16.68m
- -$18.72m
- $0.50m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.36 | ||
| Price to Tang. Book | 0.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 33.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.04% | ||
| Return on Equity | -50.49% | ||
| Operating Margin | -4735.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.17 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for CLSN
Profile Summary
Celsion Corporation is a fully integrated, clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The Company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. It has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Directors
- Jeffrey Church CFO (64)
- Khursheed Anwer EVP (61)
- Nicholas Borys EVP (61)
- Michael Tardugno DRC (70)
- Stacy Lindborg DRC (50)
- Christine Pellizzari DRC (53)
- Donald Braun IND (71)
- Augustine Chow IND (68)
- Frederick Fritz IND (70)
- Robert Hooper IND (74)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- May 17th, 2000
- Public Since
- October 27th, 1993
- No. of Shareholders
- 54,000
- No. of Employees
- 29
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 7,098,741
- Address
- 997 Lenox Dr Ste 100, LAWRENCE TOWNSHIP, 08648-2317
- Web
- http://celsion.com/
- Phone
- +1 6098969100
- Contact
- Jeffrey Church
- Auditors
- WithumSmith Brown PC
Upcoming Events for CLSN
Celsion Corp Annual Shareholders Meeting
Celsion Corp Annual Shareholders Meeting
Q2 2022 Celsion Corp Earnings Release
Q3 2022 Celsion Corp Earnings Release
Similar to CLSN
180 Life Sciences
NASDAQ Capital Market
9 Meters Biopharma
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acer Therapeutics
NASDAQ Capital Market
FAQ
What is the Celsion share price?
As of Today at 07:04 UTC, shares in Celsion are trading at $2.35. This share price information is delayed by 15 minutes.
How has the Celsion share price performed this year?
Shares in Celsion last closed at $2.35 and the price had moved by -86.01% over the past 365 days. In terms of relative price strength the Celsion share price has underperformed the S&P500 Index by -85.14% over the past year.
What are the analyst and broker recommendations for Celsion?
The overall consensus recommendation for Celsion is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Celsion dividend yield?
Celsion does not currently pay a dividend.
Does Celsion pay a dividend?
Celsion does not currently pay a dividend.
When does Celsion next pay dividends?
Celsion does not currently pay a dividend.
How do I buy Celsion shares?
To buy shares in Celsion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Celsion?
As of the previous close price of $2.35, shares in Celsion had a market capitalisation of $16.68m.
Where are Celsion shares listed?
Here are the trading details for Celsion:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CLSN
What kind of share is Celsion?
Based on an overall assessment of its quality, value and momentum Celsion is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Celsion share price forecast for 2022?
The analyst consensus target price for shares in Celsion is $32.67. That is 1290.21% above the last closing price of $2.35.
Analysts covering Celsion currently have a consensus Earnings Per Share (EPS) forecast of -$4.31 for the next financial year.
What is the trend in the Celsion share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celsion. Over the past six months, its share price has underperformed the S&P500 Index by -75.97%.
As of the last closing price of $2.35, shares in Celsion were trading -74.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Celsion PE Ratio?
The Celsion PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Celsion?
Celsion's management team is headed by:
- Jeffrey Church - CFO
- Khursheed Anwer - EVP
- Nicholas Borys - EVP
- Michael Tardugno - DRC
- Stacy Lindborg - DRC
- Christine Pellizzari - DRC
- Donald Braun - IND
- Augustine Chow - IND
- Frederick Fritz - IND
- Robert Hooper - IND